EP2714022A1 - Combinaison pour le traitement du diabète sucré - Google Patents
Combinaison pour le traitement du diabète sucréInfo
- Publication number
- EP2714022A1 EP2714022A1 EP12738248.9A EP12738248A EP2714022A1 EP 2714022 A1 EP2714022 A1 EP 2714022A1 EP 12738248 A EP12738248 A EP 12738248A EP 2714022 A1 EP2714022 A1 EP 2714022A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- clause
- combination
- metformin
- ascorbic acid
- combination according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 54
- 239000003472 antidiabetic agent Substances 0.000 claims abstract description 50
- 150000002989 phenols Chemical class 0.000 claims abstract description 49
- 238000002360 preparation method Methods 0.000 claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 230000010627 oxidative phosphorylation Effects 0.000 claims abstract description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 76
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 54
- 229960003105 metformin Drugs 0.000 claims description 47
- 235000010323 ascorbic acid Nutrition 0.000 claims description 39
- 229960005070 ascorbic acid Drugs 0.000 claims description 38
- 239000011668 ascorbic acid Substances 0.000 claims description 38
- 239000002775 capsule Substances 0.000 claims description 25
- 241000533293 Sesbania emerus Species 0.000 claims description 23
- 229940069765 bean extract Drugs 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 229940125708 antidiabetic agent Drugs 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 16
- 229940123208 Biguanide Drugs 0.000 claims description 14
- 150000004283 biguanides Chemical class 0.000 claims description 14
- 230000003178 anti-diabetic effect Effects 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 11
- 208000024891 symptom Diseases 0.000 claims description 11
- 229940123464 Thiazolidinedione Drugs 0.000 claims description 9
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 9
- 150000001467 thiazolidinediones Chemical class 0.000 claims description 9
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 8
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 8
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 8
- 229940074393 chlorogenic acid Drugs 0.000 claims description 8
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 8
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 8
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 235000013311 vegetables Nutrition 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 5
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- XHEFDIBZLJXQHF-UHFFFAOYSA-N fisetin Chemical compound C=1C(O)=CC=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 XHEFDIBZLJXQHF-UHFFFAOYSA-N 0.000 claims description 4
- 235000012054 meals Nutrition 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 claims description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 2
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 claims description 2
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 claims description 2
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 claims description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 2
- 229920002079 Ellagic acid Polymers 0.000 claims description 2
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 2
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 claims description 2
- 235000017663 capsaicin Nutrition 0.000 claims description 2
- 229960002504 capsaicin Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 235000012754 curcumin Nutrition 0.000 claims description 2
- 239000004148 curcumin Substances 0.000 claims description 2
- 229940109262 curcumin Drugs 0.000 claims description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 2
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 claims description 2
- 229960002852 ellagic acid Drugs 0.000 claims description 2
- 235000004132 ellagic acid Nutrition 0.000 claims description 2
- 235000011990 fisetin Nutrition 0.000 claims description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 2
- SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 claims description 2
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 claims description 2
- 235000021283 resveratrol Nutrition 0.000 claims description 2
- 229940016667 resveratrol Drugs 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 20
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 30
- 229940079593 drug Drugs 0.000 description 26
- 239000003814 drug Substances 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 102000004877 Insulin Human genes 0.000 description 15
- 108090001061 Insulin Proteins 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 229940125396 insulin Drugs 0.000 description 15
- 238000011161 development Methods 0.000 description 13
- 230000018109 developmental process Effects 0.000 description 13
- 229920002678 cellulose Polymers 0.000 description 12
- 239000001913 cellulose Substances 0.000 description 12
- 235000010980 cellulose Nutrition 0.000 description 12
- 229960004580 glibenclamide Drugs 0.000 description 12
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000013081 microcrystal Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 230000034659 glycolysis Effects 0.000 description 11
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 229960004329 metformin hydrochloride Drugs 0.000 description 10
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 210000003470 mitochondria Anatomy 0.000 description 9
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 9
- 208000010444 Acidosis Diseases 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 8
- 238000009825 accumulation Methods 0.000 description 8
- 230000007950 acidosis Effects 0.000 description 8
- 208000026545 acidosis disease Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
- 239000000314 lubricant Substances 0.000 description 7
- 150000008442 polyphenolic compounds Chemical class 0.000 description 7
- 235000013824 polyphenols Nutrition 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 6
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 6
- 229940100389 Sulfonylurea Drugs 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 238000005755 formation reaction Methods 0.000 description 6
- 239000007903 gelatin capsule Substances 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000005550 wet granulation Methods 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 229960001681 croscarmellose sodium Drugs 0.000 description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- -1 glinides Chemical class 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229940069328 povidone Drugs 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- HYAFETHFCAUJAY-UHFFFAOYSA-N Pioglitazone Natural products N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000023852 carbohydrate metabolic process Effects 0.000 description 3
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000009229 glucose formation Effects 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 229940107700 pyruvic acid Drugs 0.000 description 3
- 229960004586 rosiglitazone Drugs 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 150000003548 thiazolidines Chemical class 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 2
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 2
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 2
- 206010023379 Ketoacidosis Diseases 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 229960002632 acarbose Drugs 0.000 description 2
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 229960001519 exenatide Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960000346 gliclazide Drugs 0.000 description 2
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
- 229960001381 glipizide Drugs 0.000 description 2
- 229960003468 gliquidone Drugs 0.000 description 2
- 108091005995 glycated hemoglobin Proteins 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 2
- 239000000859 incretin Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229950004994 meglitinide Drugs 0.000 description 2
- 229940035732 metformin and rosiglitazone Drugs 0.000 description 2
- 229960000698 nateglinide Drugs 0.000 description 2
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 2
- 229960003271 rosiglitazone maleate Drugs 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- GDPHPXYFLPDZGH-XBTMSFKCSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 GDPHPXYFLPDZGH-XBTMSFKCSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical class CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical group OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 108700029992 Ala(2)-Arg(6)- enkephalin-Leu Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- UKMSUNONTOPOIO-UHFFFAOYSA-N Behenic acid Natural products CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical group OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000164480 Curcuma aromatica Species 0.000 description 1
- 244000303965 Cyamopsis psoralioides Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 229920003083 Kollidon® VA64 Polymers 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 1
- 229920003079 Povidone K 17 Polymers 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000381592 Senegalia polyacantha Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- NTECHUXHORNEGZ-UHFFFAOYSA-N acetyloxymethyl 3',6'-bis(acetyloxymethoxy)-2',7'-bis[3-(acetyloxymethoxy)-3-oxopropyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical compound O1C(=O)C2=CC(C(=O)OCOC(C)=O)=CC=C2C21C1=CC(CCC(=O)OCOC(C)=O)=C(OCOC(C)=O)C=C1OC1=C2C=C(CCC(=O)OCOC(=O)C)C(OCOC(C)=O)=C1 NTECHUXHORNEGZ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 230000006538 anaerobic glycolysis Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 230000000871 hypocholesterolemic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002660 insulin-secreting cell Anatomy 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940035736 metformin and pioglitazone Drugs 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000032393 negative regulation of gluconeogenesis Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960002827 pioglitazone hydrochloride Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000035924 thermogenesis Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
- 229960001641 troglitazone Drugs 0.000 description 1
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940117958 vinyl acetate Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the pharmaceutical industry and particularly medicines for the treatment of diabetes mellitus.
- Diabetes mellitus remains to be a significant problem for national public health services in virtually all countries of the world. Over the past 30 to 40 years, a significant surge in prevalence and incidence of diabetes mellitus has been evident worldwide, especially so in industrially developed countries where from 6 to 10 percent of the population suffer from diabetes mellitus and where its prevalence has a clear uptrend, primarily in age groups over 40.
- diabetes treatment plan the main goals of a diabetes treatment plan are diminution of symptoms of diabetes, improvement of life quality and prevention of both acute (hyperosmolar coma and ketoacidosis) and chronic complications, e.g. diabetic neuropathy, diabetic nephropathy and early atherosclerosis (Diabetes Control and Complications Trial Research Group; N. Engl. J. Med., 329, 977-986 (1993)).
- Chronic hyperglycemia is not just the main manifestation of diabetes constituting the basis for diagnosing the disease, but also a most important factor for the development of virtually all complications: micro- and macroangiopathies, neurophaty, nephropaty and others.
- diabetes mellitus treatment is to achieve compensation of carbohydrate metabolism for a prolonged period of time, i.e. to ensure such indicators of glucose content in blood plasma that would be substantially the same as observed in a healthy person during the day.
- the treatment of diabetes mellitus commences with prescribing a diet and dosed exercise, but in order to achieve target carbohydrate metabolism indicators, significant effort on the part of the patient are required, while as a rule, diabetes mellitus patients possess that in only an insignificant degree. That is why the main role in diabetes mellitus treatment plays drug therapy.
- Antihyperglycemic drug therapy does not just reduce glycemia indicators and thus removes clinical manifestations of the disease causes by hyperglycemia. It also breaks the "vicious circle" formed by increasing insulin deficiency due to exhaustion of insulin-secreting cells and growing hyperglycemia given the increasing insulin deficiency.
- the positive action of antihyperglycemic drugs under insulin deficiency described herein relates to a greater degree to type 2 diabetes and initial stages of type 1 diabetes. At the present time, the following groups of antihyperglycemic oral medications are used for the treatment of type 2 diabetes:
- pancreas boosting insulin production by the pancreas (sulfonylurea derivatives glibenclamide, glipizide, gliclazide, gliquidone and glimepiride);
- stimulating postprandial insulin secretion glinides, incretin mimetics, DPP-4 inhibitors, amylin and glucagon-like peptide 1 analogues
- A-glucosidase inhibitors reduce the absorption of glucose in the intestine and are usually effective at the early stages of the disease. Their side effects are associated with manifestations of meteorism and diarrhea. In most patients, the need to cease the drug administration arises within 3 years from the commencement thereof.
- Sulfonylurea derivatives stimulate the secretion of insulin by b-cells of the pancreas.
- the most commonly used sulfonylureas presently are gliclazide, glibenclamide, glipizide and gliquidone.
- Treatment with sulfonylureas is contraindicated in case of type 1 diabetes mellitus or secondary (pancreatic) diabetes mellitus, pregnancy and lactation, surgery, severe infections, injuries, allergy to sulfonylurea drugs or similar medications in the anamnesis, or the presence risk of severe hypoglycemia.
- Glinides are characterized with rapid onset and short duration of action, which enables, on the one hand, to effectively control postprandial hyperglycemia, and on the other hand, to not increase the risk of hypoglycemia.
- Preparations specifically intended to affect postprandial glucose levels are incretin mimetics, DPP-4 inhibitors, amylin analogues and glucagon-like peptide 1 analogues. These drugs compensate the existing deficiency in the secretion of hormones of the pancreas and gastrointestinal tract, affecting insulin and glucagons secretion, sense of satiety and stomach emptying. They are characterized with highly rapid onset and short antihyperglycemic effect, therefore the use thereof is not accompanied with any adverse developments causes by their influence on glucose metabolism. Rapid and short action makes the aforesaid medications useful only as postprandial antihyperglycemic drugs.
- the group of tableted antihyperglycemic biguanides is currently represented for the main part by metformin. Biguanides do not enhance insulin secretion. Their antihyperglycemic action manifests itself only where there is enough insulin in blood. Biguanides boost its action on peripheral tissues, reducing insulin resistance. Biguanides increase glucose uptake by muscles and adipose tissue. They reduce hepatic glucose production, glucose absorption in the intestine, increase glucose utilization and reduce appetite. It is contraindicated to prescribe biguanides with renal dysfunction, hypoxic conditions of any etiology (heart failure, lung diseases, anaemia, infectious diseases), acute complications of diabetes mellitus, alcohol abuse, lactacidemia in the anamnesis.
- antihyperglycemic sulfanilamide preparations and biguanides may cause side effects in the form of gastrointestinal disorders, skin allergies, and hypoglycemic states due to the closeness of therapeutic and toxic doses of these drugs.
- Thiazolidinediones affect the glycemic control by reducing insulin resistance in peripheral tissues, especially adipose tissue, and also reduce hepatic glucose production. Preparations of this group do not cause hypoglycemia but may contribute to weight gain. These drugs are contraindicated for patients with symptoms of heart failure and manifestations of preproliferative and proliferative stages of diabetic retinopathy.
- antihyperglycemic monotherapy prove ineffective, the desired effect may be achieved sometime by combining antihyperglycemic preparations.
- the following combinations of oral antihyperglycemic preparations are possible: sulfonylurea preparations and thiazolidinediones, metformin and meglitinides, metformin and thiazolidinediones, sulfonylurea preparations and a-glucosidase inhibitors. If glycemic control is not achieved by a combination of oral antihyperglycemic preparations, combination therapy with insulin and biguanides, or monotherapy with insulin will be prescribed.
- the oral antihyperglycemic preparation of combined action - Glibomet consists of 2.5 mg of glibenclamide and 400 mg of metformin.
- Glibenclamide contained in the drug stimulates insulin secretion by b-cells of the pancreas, while metformin lowers insulin resistance mainly in the liver, which is accompanied by inhibition of gluconeogenesis, decreasing the rate of glucose formation in the liver and admission thereof into the circulatory system.
- the use of combination drugs enhances the antihyperglycemic effect, but keeps intact the threat of lactacidosis that accompanies the use of metformin.
- Glitazone may be represented by pioglitazone, rosiglitazone or troglitazone (RU 2280447, 15.09.2000).
- the combination medication may take the form of a combined preparation or a pharmaceutical composition.
- Such pharmaceutical composition may comprise, as a third antidiabetic agent, metformin in a pharmaceutical carrier.
- metformin in a pharmaceutical carrier.
- the combined use of nateglinide with another antidiabetic agent ensures synergistic therapeutic effect for type 2 diabetes and a prolonged duration of the drug action, which results in the putting off of insulin use to a later date.
- the downside of the combinations is the use of glitazone and metformin, both of which may contribute to the development of lactacidosis.
- a medication for the treatment of diabetes mellitus comprising a combination of exenatide and dalargin in effective amounts (RU 2413528 18.01.2007).
- This combination is a combined drug and ensures effective treatment of diabetes mellitus by means of potentiation of hypoglycemic and hypocholesterolemic action of exenatide.
- the downside of the combinations is the preferred use of the injection form of administration.
- a medication for the treatment of insulin-independent type 2 diabetes mellitus, which comprises a combination of metformin and glibenclamide in effective amounts, and a method of treating insulin independent diabetes or hyperglycemia with glibenclamide that forms part of a combination medication for oral administration with an area of powder particle surface of from 1.7 to 2.2 m 2 /g (RU > 2286788 12.07.1999).
- the invention ensures bioavailability of glibenclamide in the composition of metformin- comprising medications comparable to the bioavailability of glibenclamide monoforms.
- metformin in the proposed preparation results in the need to take into account the increased likelihood of lactacidosis.
- antihyperglycemic drugs for oral administration currently used solve the problem of reducing blood sugar by different mechanisms, hence they are effective only under certain conditions. Vague manifestation of symptoms of the principal disease and concurrent conditions that cause contraindications in some patient subgroups result in undesirable side effects.
- One of the most significant contraindications is a predisposition to lactacidosis.
- the task of increasing the discharge of reduced cofactors might be solved by means of the use, in the composition of antidiabetic drugs, of such components that ensure an enhanced consumption of reduced cofactors in intracellular processes.
- ascorbic acid and derivatives thereof improves bioavailability of natural phenolic compounds.
- the effect of the application of that composition consists in the reduction of glucose level in blood, glycated hemoglobin, cholesterol and triglycerides.
- a method of treating diabetes or diabetes induced disorders in a patient is known by means of injection of a composition comprising coffee beans (US 2009017597).
- the effect of the application of that composition in treating diabetes or diabetes induced disorders in patients is defined as stabilization of blood sugar, glycated hemoglobin AIC, triglyceride and low-density lipoprotein levels, or as blood sugar level normalization.
- the target purpose is achieving direct therapeutic effect on diabetes on account of antioxidant action of the given composition.
- compositions comprising antidiabetic agents, in particular metformin, and methods of diabetes treatment that include prescribing of antidiabetic preparations to a patient (Balabolkin M.I., Diabetology, Moscow, Meditsina, 2000; Ametov A.S. Type 2 Diabetes Mellitus: Basics of Pathogenesis and Therapy. Moscow, 2003)
- the purpose of this invention is the development of a combination drug for treating diabetes that would reduce the incidence of side effects of antihyperglycemic preparation application due to the accelerated utilization of glycolysis products, and also reduce generation of lactic acid, and creating an opportunity to use such medication in all-round diabetes therapy.
- the technical effect of the invention consists in the reduction of the risk of lactacidosis development in using known antihyperglycemic agents.
- the essence of the invention consists in the use of combinations of known antihyperglycemic substances along with natural phenolic compounds capable of uncoupling oxidative phosphorylation, and, additionally, with ascorbic acid improving bioavailability of natural phenolic compounds by maintaining them in an active phenolic state.
- the authors have suggested a combination for treating diabetes, including at least one antidiabetic agent and a natural phenolic compound or a mixture of such compounds capable of uncoupling oxidative phosphorylation.
- the combination comprises a natural phenolic compound or a mixture of such compounds in an amount of at least 2 %.
- the antidiabetic agent in a combination is selected from a group comprising biguanides, thiazolidinediones or compositions thereof.
- the natural phenolic compound capable of uncoupling oxidative phosphorylation to be used in a combination is selected from the group consisting of chlorogenic acid or Epigallocatechin-3-gallate or Epicatechin-3-gallate or ellagic acid or quercetin or dihydroquercetin or fisetin or curcumin or resveratrol or capsaicin or caffeic acid phenethyl ester.
- Such compounds are known to be present in the composition of green coffee bean extracts, green tea, pomegranate, catechu acacia, curcuma, Japanese knotweed, hot pepper, propolis and a number of other products of vegetable or animal origin.
- the said natural phenolic compounds may be isolated from products containing them by known methods, or obtained synthetically, or used in the form of concentrated extracts. According to the research conducted by the authors, an effective amount of natural phenolic compounds (one-time dose) is from 10 to 200 mg.
- the mixture of natural phenolic compounds in the combination consists of a vegetable extract.
- the combination comprises metformin as an antidiabetic agent and coffee bean extract as a vegetable extract.
- the combination comprises metformin as an antidiabetic agent and green coffee bean extract as a vegetable extract.
- the combination additionally comprises ascorbic acid or pharmaceutically acceptable derivatives thereof in an amount of at least 25 % of the amount of green coffee bean extract.
- compositions for the treatment of diabetes and complications thereof constituting a composition medication including a combination of at least one antidiabetic agent and a natural phenolic compound or a mixture of such compounds, and a pharmaceutically acceptable carrier.
- the preferable embodiment is a composition comprising metformin, green coffee bean extract and ascorbic acid in therapeutically effective amounts as an antidiabetic agent.
- mass amounts of metformin, green coffee bean extract and ascorbic acid preferably relate to each other in proportion of from 100:20: 10 to 100:40:30.
- the composition may be executed in the form of a powder, granules, tablets, pellets, capsules, candies, suspensions, emulsions or solubilisate, and comprise auxiliary substances, in particular, fillers (silicon dioxide, microcrystal cellulose, croscarmellose sodium etc.), binders (polyvinylpyrrolidone, vinylpyrrolidone and vinylacetate copolymer etc.), lubricants (magnesium stearate etc.), emulsifiers (oxyethylated castor wax, lecitin etc.), solubilizers (polysorbates, poloxamers, etc.), prolongators (behenic acid glycerides, hydroxypropylmethylcellulose etc.), and correctives (fructose, lactose, sorbite etc.).
- fillers silicon dioxide, microcrystal cellulose, croscarmellose sodium etc.
- binders polyvinylpyrrolidone, vinylpyrrol
- Antidiabetic agents in the composition are used in doses recommended for their individual administration.
- the frequency of administration of the claimed composition coincides with the frequency of administration of antidiabetic agents - components thereof.
- the period of administration should is be as long as any lactacidosis symptoms persist, but two weeks in the least. It is preferable that the patient should continue taking the claimed composition after the restoration of pH values and lactate blood content, because it will lower the risk of the recurrence of lactacidosis.
- the authors have also proposed a pharmaceutical set effective for treating diabetes, including a combination of at least one antidiabetic agent and one natural phenolic compound or a mixture of such compounds.
- Such set constitutes an individually manufactured preparation composed of antidiabetic agents, and another individually manufactured preparation comprising natural phenolic compounds or a mixture thereof.
- Such preparations may comprise ascorbic acid or pharmaceutically acceptable derivatives thereof.
- the said preparation composed of antidiabetic agents may contain, for example, metformin hydrochloride and auxiliary substances (hydroxypropylmethylcellulose, microcrystal cellulose, povidone, magnesium stearate) and be in the tablet form.
- the preparation comprising natural phenolic compounds may contain, for example, green coffee bean extract (50-55 % polyphenols), ascorbic acid and microcrystal cellulose as an auxiliary substance. Such composition may be placed in a hard gelatin capsule.
- Tablets and capsules may be packaged in blisters or flasks with appropriate marking and put in a common box with an equal number of tablets and capsules in it.
- one, two and three tablets and capsules may be prescribed for a single dose.
- a method of combined diabetes therapy includes prescribing to a patient a combination consisting of at least one antidiabetic agent and a natural phenolic compound or a mixture of such compounds.
- the claimed pharmaceutical composition may be used as a combination.
- the pharmaceutical composition is used in treating diabetes mellitus on occurrence of lactacidosis symptoms in the patient or at the beginning of diabetes mellitus treatment in case there is information on the patient having predisposition to acidosis in the anamnesis.
- the composition is prescribed in an amount corresponding to the therapeutically effective dose of the particular antidiabetic antihyperglycemic agent it comprises, with the division of the daily dose into 2 or 3 one-time doses. It corresponds to the intake of 2-3 capsules or tablets comprising the claimed composition, 2 or 3 times daily at or after meals.
- the patient takes the composition till the symptoms of acidosis are eliminated but no less than two weeks in the least.
- the claimed combination may be used in the form of a pharmaceutical set.
- the pharmaceutical set according to the present invention is used where there are indications with regard to the patient for the use of the claimed combination in the form of a pharmaceutical composition.
- the amount of combination medication in the form of a pharmaceutical set is determined by the therapeutically effective dose of the particular antidiabetic antihyperglycemic agent it comprises.
- the combination is prescribed in 1 or 2 sets per intake, 2-3 times daily, at or after meals.
- the administration of the pharmaceutical set is continued till the elimination of acidosis symptoms in the patient, but no less than for two weeks. That said, the preferred option is to continue the administration of the claimed set in the subsequent treatment of diabetes mellitus. In that period, depending on the clinical laboratory examination results, individual components of an appropriate type may be added to one-time doses of the set for the purpose of enhancing the antihyperglycemic effect or antiacidosis effect.
- the claimant also intends to protect the application of natural phenolic compounds capable of uncoupling oxidative phosphorylation, or a mixture of such compounds, in treating diabetes with the use of antihyperglycemic preparations as an agent suppressing the development of lactacidosis.
- a combination for treating diabetes according to the present invention represented by a pharmaceutical composition encapsulated in a hard gelatin capsule.
- the capsule comprises a mixture of 250 mg of metformin hydrochloride, 125 mg of green coffee bean extract (50-55 % polyphenols) and 25 mg of microcrystal cellulose.
- the combination is prescribed in one-time doses of 2 or 3 capsules.
- Example 2 The combination is prescribed in one-time doses of 2 or 3 capsules.
- a combination for treating diabetes according to the present invention represented by a pharmaceutical composition encapsulated in a hard gelatin capsule.
- the capsule comprises a mixture of 250 mg of metformin hydrochloride, 60 mg of green coffee bean extract (50-55 % polyphenols), 36.5 mg of ascorbic acid and 3.5 mg of silicon dioxide.
- the combination is prescribed to be taken 2-3 capsules at a time.
- a combination for treating diabetes according to the present invention represented by a pharmaceutical composition encapsulated in a hard gelatin capsule.
- the capsule comprises a mixture of 250 mg of metformin hydrochloride, 1 mg of rosiglitazone maleate, 50 mg of chlorogenic acid, 74 mg of ascorbic acid and 25 mg of microcrystal cellulose.
- the combination is prescribed to be taken 2-3 capsules at a time.
- a combination for treating diabetes according to the present invention represented by a pharmaceutical composition in a tablet form.
- the tablet comprises 250 mg of metformin hydrochloride, 60 mg of chlorogenic acid, and auxiliary substances (microcrystal cellulose, croscarmellose sodium, polyvinylpyrrolidone, magnesium stearate, hydroxypropylmethylcellulose, polyethyleneglycol, titanium dioxide).
- auxiliary substances microcrystal cellulose, croscarmellose sodium, polyvinylpyrrolidone, magnesium stearate, hydroxypropylmethylcellulose, polyethyleneglycol, titanium dioxide.
- the tablet is manufactured by a method comprising the production of granules by means of wet granulation of a mixture of metformin and chlorogenic acid with the addition of a binder, the subsequent mixing of granules with a solubilizer and a lubricant, tableting the mixture and coating the resultant tablets with hydrophilic polymer film.
- the combination is prescribed to be taken 2-3 tablets at a time.
- a combination for treating diabetes according to the present invention represented by a pharmaceutical composition in a tablet form.
- the tablet comprises 250 mg of metformin hydrochloride, 1.25 mg of glibenclamide, 30 mg of chlorogenic acid, 40 mg of ascorbic acid and auxiliary substances (microcrystal cellulose, croscarmellose sodium, polyvinylpyrrolidone, magnesium stearate, hydroxypropylmethylcellulose, polyethyleneglycol, titanium dioxide).
- auxiliary substances microcrystal cellulose, croscarmellose sodium, polyvinylpyrrolidone, magnesium stearate, hydroxypropylmethylcellulose, polyethyleneglycol, titanium dioxide.
- the tablet is manufactured by a method comprising the production of granules by means of wet granulation of a mixture of metformin, glibenclamide, chlorogenic and ascorbic acids with the addition of a binder, the subsequent mixing of granules with a solubilizer and a lubricant, tableting the mixture and coating the resultant tablets with hydrophilic polymer film.
- the combination is prescribed to be taken 2-3 tablets at a time.
- a combination for treating diabetes according to the present invention represented by a pharmaceutical set consisting of separately manufactured tablets, which comprises an antidiabetic antihyperglycemic agent and a tablet containing a natural phenolic compound.
- the tablet containing antihyperglycemic substances includes 500 mg of metformin hydrochloride, 15 mg of pioglitazone hydrochloride and auxiliary substances (microcrystal cellulose, croscarmellose sodium, polyvinylpyrrolidone, magnesium stearate, hydroxypropylmethylcellulose, polyethyleneglycol, titanium dioxide, talc)
- auxiliary substances microcrystal cellulose, croscarmellose sodium, polyvinylpyrrolidone, magnesium stearate, hydroxypropylmethylcellulose, polyethyleneglycol, titanium dioxide, talc
- the tablet is manufactured by a method comprising the production of granules by means of wet granulation of a mixture of metformin and pioglitazone with the addition of a binder, the subsequent mixing of granules with a solubilizer and a lubricant, tableting the mixture and coating the resultant tablets with hydrophilic polymer film.
- the tablet containing a polyphenolic compound includes 100 mg of chlorogenic acid and auxiliary substances (hydroxypropylmethylcellulose, microcrystal cellulose, povidone, magnesium stearate).
- the tablet is manufactured by a method comprising the production of granules by means of wet granulation of a mixture of chlorogenic acid and a binder, the subsequent mixing of granules with a solubilizer and a lubricant, and tableting the mixture.
- Tablets containing antihyperglycemic agents, on the one hand, and tablets containing a natural phenolic compound, on the other hand, are packaged in blisters or flasks with different marking and placed in a common box with an equal number of tablets of each type in the box.
- the combination is prescribed to be taken one or two tablets of each type at a time.
- a combination for treating diabetes according to the present invention represented by a pharmaceutical set consisting of separately manufactured tablets containing an antidiabetic antihyperglycemic agent, and capsules containing a mixture of a natural phenolic compound with ascorbic acid.
- the tablet comprises 500 mg of metformin hydrochloride and auxiliary substances (hydroxypropylmethylcellulose, microcrystal cellulose, povidone, magnesium stearate).
- the tablet is manufactured by a method comprising the production of granules by means of wet granulation of a mixture of metformin with the addition of a binder, the subsequent mixing of granules with a solubilizer and a lubricant, and tableting the mixture.
- the capsule comprises a mixture of lOO mg of green coffee bean extract (50-55 % polyphenols), 75 mg of ascorbic acid and 25 mg of microcrystal cellulose.
- Tablets and capsules are packaged in blisters or flasks with a respective marking and placed in a common box with an equal number of tablets and capsules in the box.
- the combination is prescribed to be taken one (1 tablet and 1 capsule) or two (2 tablets and 2 capsules) sets at a time.
- a combination for treating diabetes according to the present invention represented by a pharmaceutical set consisting of separately manufactured tablets containing an antidiabetic antihyperglycemic agent, and tablets containing a mixture of a natural phenolic compound with ascorbic acid.
- the tablet containing an antihyperglycemic agent comprises 500 mg of metformin hydrochloride, 5 mg of glibenclamide and auxiliary substances (croscarmellose sodium, magnesium stearate, starch, microcrystal cellulose, povidone, lactose monohydrate).
- auxiliary substances croscarmellose sodium, magnesium stearate, starch, microcrystal cellulose, povidone, lactose monohydrate.
- the tablet is manufactured by a method comprising the production of granules by means of wet granulation of a mixture of metformin and glibenclamide with the addition of a binder, the subsequent mixing of granules with a solubilizer and a lubricant, and tableting the mixture.
- the tablet for a prolonged release of active substances comprising 200 mg of green coffee bean extract, 50 mg of ascorbic acid and auxiliary substances (compritol 888 ATO, kollidon VA64, kollidon 17PF, magnesium stearate).
- the tablet is manufactured by the direct compression method of tablet masses in the form of granulates obtained by disintegration of direct-compression cakes of a mixture of active substances, and auxiliary components.
- Tablets containing antihyperglycemic agents, on the one hand, and tablets containing a mixture of a natural phenolic compound and ascorbic acid, on the other hand, are packaged in blisters or flasks with different marking and placed in a common box with an equal number of tablets of each type in the box.
- the combination is prescribed to be taken one or two tablets of each type at a time.
- a combination for treating diabetes according to the present invention represented by a pharmaceutical set consisting of separately manufactured tablets containing an antidiabetic antihyperglycemic agent, and soft gelatin capsules containing a suspension of a mixture of a natural phenolic compound with ascorbic acid.
- a soft gelatin capsule comprising a suspension of a mixture of 75 mg of green coffee bean extract (50-55 % polyphenols) and 50 mg of ascorbic acid in 150 mg of polysorbate 80 (Tween 80).
- Suspension for the filling of capsules is produced in the form of homogeneous pasty body gradually admixing a premixed preparation of green coffee bean extract with ascorbic acid to polysorbate 80 under constant stirring in a vacuum reactor.
- Tablets and capsules are packaged in blisters or flasks with a respective marking and placed in a common box with an equal number of tablets and capsules in the box.
- the suppression of intracellular pH decrease induced in the MDCK continuous line cells (dog's liver cells) by means of natural phenolic compounds capable of uncoupling oxidative phosphorylation in mitochondria was performed by means of adding metformin and rosiglitazone to cell culture medium.
- a MDCK cell culture was grown in DMEM medium with the addition of a 10% calf serum at 37°C and 5% of C02 (pH 7.4). After the formation of an uninterrupted monolayer the cells were transferred to a suspension with the use of a Trypsin-EDTA solution. When cells were completely separated in order to halt any further action of EDTA-Trypsin, fetal calf serum and DMEM medium were introduced into the culture flask in equal proportions (1 :1). The cells were washed twice with the DMEM medium.
- cell suspensions were prepared in culture flasks with a concentration of 1 ⁇ 10 6 cells/mL in Krebs- Henseleit medium containing 10 MM of d-glucose, with the addition of one of the following antihyperglycemic substances: metformin hydrochloride (5 MM) or rosiglitazone maleate (25 ⁇ ), and one natural phenolic compound (50 ⁇ ).
- metformin hydrochloride 5 MM
- rosiglitazone maleate 25 ⁇
- one natural phenolic compound 50 ⁇
- the suspension was incubated for 60 minutes at 37°C under stirring every 10 minutes by means of shaking the test-tubes. On completion of the incubation, the cells were precipitated by centrifuging, and re-suspended in Krebs-Henseleit medium containing 10 MM of d-glucose and 5 ⁇ of pH-susceptible dye 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM). The resultant suspension was incubated 25 minutes at 37°C to induce the dye absorption by the cells. Then the suspension was washed three times in Krebs- Henseleit medium where HEPES was replaced with bicarbonate.
- Krebs-Henseleit medium pH-susceptible dye 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein acetoxymethyl ester
- the resultant cells were suspended in the same buffer with a concentration of 1 ⁇ 10 6 cells/mL and introduced into a microcuvette for fluorescence measurements, thermostated at 37°C. Fluorescence measurements were conducted on a Perkin Elmer LS-5 spectrofluorometer with fluorescence registered at 530 nm and excitation at two wavelengths: 490 nm (fluorescence susceptible to pH) and 440 nm (isobestic point).
- the ratio of fluorescence at 490 nm to fluorescence at 440 nm was used to calculate the intracellular pH based on calibration correlation obtained with the use of a cell suspension 1 ⁇ 10 6 cells/mL in Krebs-Henseleit medium with different pH values (from 6.5 to 7.5) containing H+/K+ ionophore nigericin (10 ⁇ g/mL).
- tablette 1 demonstrate the ability of natural phenolic compounds, capable of uncoupling oxidative phosphorylation, to prevent the reduction of intracellular pH induced in the MDCK continuous line cells by the addition to a cell culture medium of antihyperglycemic agents from the groups of biguanides (metformin) and thiazolidinediones (rosiglitazone).
- Sprague Dawley rats aged 8 months with a body mass of 250-280 g were used. Animals were held under the light/darkness cycle of 12 hours each, with a free access to water and feedstuff for rodents. Twelve hours prior to the start of an experiment, the animals were denied access to food but continued to enjoy free access to water. Metformin was injected directly into the tail vein in a dose of 250 mg/kg in the form of a 2.5 % solution in physiological solution four times with intervals of 1 hour. Half an hour before the first injection of metformin, the laboratory animals orally received a solution or suspension of natural phenolic compounds in water or in an aqueous solution of ascorbic acid.
- the dose of natural phenolic compounds amounted to 5 mg/kg, and that of ascorbic acid - 2.5 mg/kg.
- Control groups were represented by intact animals; animals that received only metformin; and animals that received metformin and an ascorbic acid solution without natural phenolic compounds.
- the supernatant (0.4 mL) was collected into new microcentrifuge tubes, acid was neutralized by the addition of a 25 ⁇ , of 5 M potassium carbonate solution, and residue separated by centrifuging for 5 minutes at 10,000g and 4°C. The collected supernatant was immediately used to determine the lactate content according to the fluorometric methodology with the use of a standard set of reagents adapted to the use in microcuvettes on Perkin Elmer LS-5 spectrofluorometer.
- tablette 2 demonstrate the ability of natural phenolic compounds capable of uncoupling oxidative phosphorylation in mitochondria to suppress lactic acid accumulation and lactacidosis development, in particular, one induced by the administration of large doses of antihyperglycemic agent metformin.
- the administration of the aforementioned phenolic compounds along with ascorbic acid contributes to the enhancement of the recorded antiacidosis effect, which confirms benefit of the combined use of these substances according to the invention.
- Patient V. 47 y/o, diagnosed with type 2 diabetes for the first time.
- antihyperglycemic therapy was prescribed in the form of metformin monopreparation, starting with 500 mg daily.
- metformin was increased to 500 mg twice daily.
- the clinical laboratory examination conducted a week later detected weak lactacidosis symptoms in the patient (see table 3), which manifested themselves by blood lactate content slightly exceeding the upper range, and blood pH declining lower than the lower range.
- the tendency to develop acidosis was related to a hepatic insufficiency, in turn related to hepatitis in the medical history.
- the patient was switched to two combinations daily consisting of a tablet of antihyperglycemic agent and a capsule comprising a mixture of a natural phenolic compound with ascorbic acid according to example 7 for a period of two weeks.
- the clinical laboratory examination conducted in due time established lactate content and blood pH normalization. Normal values of the said indicators remained stable after the addition, to the two daily combinations according to example 7, of an additional 500 mg tablet of metformin monpreparation (to the total of 500 mg x 3 daily) for the period of four weeks, with a subsequent transition to the administration of metformin monopreparation in the dosage of 500 mg x 3 daily for the period of the following four weeks.
- Intracellular pH in cells under incubation in a culture medium without antihyperglycemic substances and substances capable of uncoupling oxidative phosphorylation in mitochondria was equal to 7.43 1 0.06.
- the recorded decline of intracellular pH on the addition to the incubation medium of just antihyperglycemic agents corresponds to ⁇ 0.05 according to Student's /-test.
- Lactate content in blood serum of intact animals is 1.64 ⁇ 0.19 mM.
- the recorded increase of lactate content caused by metformin administration corresponds to P ⁇ 0.05 according to Student's i-test.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Medical Informatics (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
L'invention concerne une combinaison pour le traitement du diabète sucré qui peut être réalisée sous la forme d'une composition pharmaceutique ou d'un ensemble pharmaceutique. La combinaison comprend des agents anti-hyperglycémiques et des composés phénoliques naturels aptes à découpler une phosphorylation oxydante. Ladite composition donne la possibilité de réduire l'incidence d'effets secondaires résultant de l'utilisation de préparations anti-hyperglycémiques, en particulier le risque d'acidose lactique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011122374/15A RU2451506C1 (ru) | 2011-06-02 | 2011-06-02 | Комбинация для лечения сахарного диабета и его осложнений |
PCT/RU2012/000254 WO2012166008A1 (fr) | 2011-06-02 | 2012-04-05 | Combinaison pour le traitement du diabète sucré |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2714022A1 true EP2714022A1 (fr) | 2014-04-09 |
Family
ID=46231593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12738248.9A Withdrawn EP2714022A1 (fr) | 2011-06-02 | 2012-04-05 | Combinaison pour le traitement du diabète sucré |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP2714022A1 (fr) |
JP (1) | JP2014527506A (fr) |
KR (1) | KR101567660B1 (fr) |
CN (1) | CN103402506A (fr) |
EA (1) | EA028394B1 (fr) |
RU (1) | RU2451506C1 (fr) |
WO (1) | WO2012166008A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2548731C2 (ru) * | 2012-10-24 | 2015-04-20 | Федеральное Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Новосибирский Государственный Педагогический Университет" | Средство и способ комплексной терапии больных сахарным диабетом |
WO2014189152A1 (fr) | 2013-05-24 | 2014-11-27 | Otsuka Pharmaceutical Co., Ltd. | Combinaison pharmaceutique comprenant de la metformine et de la dihydroquercétine et son utilisation pour le traitement du cancer |
US10442610B2 (en) | 2014-03-11 | 2019-10-15 | Starbucks Corporation | Pod-based restrictors and methods |
CN105902761A (zh) * | 2016-06-16 | 2016-08-31 | 河南中医学院 | 一种槐花珍在制备治疗高血糖和糖尿病药物中的应用 |
FR3062795B1 (fr) * | 2017-02-16 | 2019-06-07 | Valbiotis | Principe actif pharmaceutique et utilisation en particulier dans la prevention et le traitement des dereglements metaboliques chez l'homme et l'animal. |
RU2687256C1 (ru) * | 2018-03-26 | 2019-05-08 | Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет | Способ персонализированного лечения хронической болезни почек у больных с диабетической нефропатией |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1004304A1 (fr) * | 1996-12-24 | 2000-05-31 | Sumitomo Pharmaceuticals Company, Limited | Composition contenant de l'acide ascorbique |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69818444T2 (de) | 1998-07-15 | 2004-05-06 | Merck Santé | Tabletten enthaltend eine Kombination von Glibenclamid und Metformin |
KR20000019716A (ko) * | 1998-09-15 | 2000-04-15 | 박호군 | 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물 |
RU2280447C2 (ru) | 1999-09-17 | 2006-07-27 | Новартис Аг | Способ лечения нарушений метаболизма, прежде всего диабета или заболеваний или состояний, связанных с диабетом |
JP4719372B2 (ja) * | 2000-06-21 | 2011-07-06 | 花王株式会社 | Ppar依存的遺伝子転写活性化剤 |
WO2002009734A1 (fr) * | 2000-08-01 | 2002-02-07 | Oryza Oil & Fat Chemical Co.,Ltd. | Inhibiteurs d'absorption de sucre et leur procede de production |
JP2003300904A (ja) * | 2002-04-05 | 2003-10-21 | National Cardiovascular Center | 循環器系障害の進展を抑制する医薬組成物 |
CN100518733C (zh) * | 2003-09-23 | 2009-07-29 | 帝斯曼知识产权资产管理有限公司 | 用于治疗和预防糖尿病的组合物 |
CN1925862A (zh) * | 2003-10-10 | 2007-03-07 | 雷斯弗洛吉克斯公司 | 与egr-1增强子元件有关的疾病的治疗 |
RU2284829C2 (ru) * | 2004-12-16 | 2006-10-10 | Пятигорская государственная фармацевтическая академия | Антидиабетический сбор |
WO2006079056A1 (fr) * | 2005-01-20 | 2006-07-27 | Stephen Holt | Compositions vegetales a base d'hoodia |
KR20080028415A (ko) * | 2005-07-12 | 2008-03-31 | 다이이찌 산쿄 가부시키가이샤 | PPARγ 애고니스트를 함유하는 의약 조성물 |
JP5246833B2 (ja) * | 2005-12-16 | 2013-07-24 | 独立行政法人産業技術総合研究所 | アディポネクチン産生増強剤 |
JP5246834B2 (ja) * | 2005-12-27 | 2013-07-24 | 独立行政法人産業技術総合研究所 | アディポネクチン産生強化剤 |
CN101176786A (zh) * | 2006-11-08 | 2008-05-14 | 中国科学院上海生命科学研究院 | 增加胰岛素敏感性的方法和组合物 |
RU2413528C2 (ru) | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения |
TW200903710A (en) | 2007-07-11 | 2009-01-16 | Promos Technologies Inc | Manufacturing method for shallow trench isolation |
US20090175973A1 (en) * | 2007-09-05 | 2009-07-09 | Nina Vikhrieva | Coffee cherry compositions and methods for their use in the treatment of diabetes and diabetes related disorders |
CN101250106B (zh) * | 2008-03-27 | 2011-05-18 | 北京市农林科学院 | 一种提取绿原酸的方法 |
JP5054594B2 (ja) * | 2008-03-31 | 2012-10-24 | 花王株式会社 | 脂質代謝改善剤 |
RU2378003C1 (ru) * | 2008-06-06 | 2010-01-10 | Сергей Юрьевич Лешков | Фармацевтическая композиция на основе экстракта зеленой ягоды кофе, способ получения и применения |
US20100215782A1 (en) | 2008-10-22 | 2010-08-26 | Metaproteomics, Llc | Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis |
WO2010089874A1 (fr) * | 2009-02-05 | 2010-08-12 | フジッコ株式会社 | Amplificateur de l'expression du ppar-γ, amplificateur de la production d'adiponectine, activateur de l'ucp et préparation pharmaceutique, aliment ou boisson renfermant l'un quelconque de ces agents |
WO2010118789A1 (fr) * | 2009-04-17 | 2010-10-21 | Dsm Ip Assets B.V. | Combinaisons d'hydroxytyrosol pour l'amplification de la fonction mitochondriale et la production d'énergie |
US20120129923A1 (en) * | 2009-05-20 | 2012-05-24 | Nutracryst Therapeutics Private Limited | Pharmaceutical co-crystals of quercetin |
JP2011063557A (ja) * | 2009-09-18 | 2011-03-31 | Lion Corp | Ppar活性化剤 |
ES2356536B1 (es) * | 2009-09-23 | 2012-02-13 | Probelte Pharma, Sa | Una composición de uso como prebiótico que contiene un extracto de granada y un alimento que incluye dicha composición. |
CN101851221B (zh) * | 2010-05-27 | 2012-09-05 | 东北林业大学 | 一种从落叶松中制备二氢槲皮素的方法 |
-
2011
- 2011-06-02 RU RU2011122374/15A patent/RU2451506C1/ru not_active IP Right Cessation
-
2012
- 2012-04-05 CN CN2012800085850A patent/CN103402506A/zh active Pending
- 2012-04-05 JP JP2014513476A patent/JP2014527506A/ja active Pending
- 2012-04-05 WO PCT/RU2012/000254 patent/WO2012166008A1/fr active Application Filing
- 2012-04-05 EP EP12738248.9A patent/EP2714022A1/fr not_active Withdrawn
- 2012-04-05 EA EA201301308A patent/EA028394B1/ru not_active IP Right Cessation
- 2012-04-05 KR KR1020137032709A patent/KR101567660B1/ko not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1004304A1 (fr) * | 1996-12-24 | 2000-05-31 | Sumitomo Pharmaceuticals Company, Limited | Composition contenant de l'acide ascorbique |
Also Published As
Publication number | Publication date |
---|---|
KR20140008452A (ko) | 2014-01-21 |
WO2012166008A1 (fr) | 2012-12-06 |
EA028394B1 (ru) | 2017-11-30 |
JP2014527506A (ja) | 2014-10-16 |
CN103402506A (zh) | 2013-11-20 |
KR101567660B1 (ko) | 2015-11-10 |
RU2451506C1 (ru) | 2012-05-27 |
EA201301308A1 (ru) | 2014-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012166008A1 (fr) | Combinaison pour le traitement du diabète sucré | |
US9561199B2 (en) | Activation of AMP-protein activated kinase by oxaloacetate compounds | |
CN104349790A (zh) | 用于治疗糖尿病的葡萄糖激酶活化剂组合物 | |
US20180333399A1 (en) | Method of improving liver function | |
WO2009155753A1 (fr) | Utilisation d’un dérivé d’inositol ou de sels de celui-ci dans la fabrication de médicaments en tant qu’inhibiteurs de glycosidase ou de médicaments pour traiter le diabète | |
RU2664442C2 (ru) | Способ снижения веса | |
WO2021115156A1 (fr) | Composition contenant du pyruvate de sodium et son utilisation | |
CA3104916C (fr) | Composition pharmaceutique destinee a prevenir le diabete et utilisation correspondante | |
KR20070016417A (ko) | 복어 추출물을 포함하는 비만 또는 당뇨성 질환의 예방또는 치료용 약학 조성물 | |
AU2016206292B2 (en) | A method of improving liver function | |
Ke et al. | Efficacy and safety of a combination of miglitol, metformin and insulin aspart in the treatment of type 2 diabetes | |
WO2022061962A1 (fr) | Méthode pour intervenir efficacement sur le diabète à l'aide d'un inhibiteur ou d'un antagoniste du transporteur d'acides aminés de type l | |
WO2024060359A1 (fr) | Utilisation d'un composé glycérophospholipide dans la prévention et le traitement de l'hyperlipidémie, de l'athérosclérose, de la stéatose hépatique non alcoolique et de l'obésité | |
CN105030806A (zh) | 一种治疗糖尿病的药物组合物及其用途 | |
Rathor et al. | Understanding the role of angiogenesis, inflammation and oxidative stress in diabetes mellitus: Insights into the past, present and future trends | |
CN112494509A (zh) | 一种防治阿尔茨海默症的组合物及应用 | |
CN113559088A (zh) | 一种含二甲双胍和西格列汀的复方降糖药物制剂 | |
CN110575447A (zh) | 一种用于防治糖尿病的药物组合物及其用途 | |
MX2012014757A (es) | Composicion farmaceutica de una meglitinida y una tiazolidinediona o sus sales farmaceuticamente aceptables y su uso. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20131213 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20160926 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20181009 |